Last reviewed · How we verify
Omeprazole and domperidone
At a glance
| Generic name | Omeprazole and domperidone |
|---|---|
| Also known as | omipak , motilium |
| Sponsor | Mansoura University Children Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Pepsin Assay in Wheezy Infants (PHASE4)
- A New System for GERD Diagnosis and Treatment
- Gastroesophageal Reflux Treatment in Scleroderma (PHASE3)
- Prophylaxis for Aspiration of Gastric Contents. (PHASE4)
- An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide
- vMII for Measurement of Oesophageal Bolus Transport and Reflux (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omeprazole and domperidone CI brief — competitive landscape report
- Omeprazole and domperidone updates RSS · CI watch RSS
- Mansoura University Children Hospital portfolio CI